MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a specific emphasis on dermatology and rheumatology [1]. Class Action Details - The class action was filed on behalf of all investors who purchased or acquired MoonLake's common stock during the class period from March 10, 2024, to September 29, 2025 [1]. - The lawsuit claims that the company failed to disclose critical information regarding the differences between its drug SLK and monoclonal antibodies, including the lack of superior clinical benefits and efficacy [3]. Allegations Against the Company - The complaint outlines several key allegations: 1. SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. 2. SLK's unique Nanobody structure does not provide a clinical advantage over BIMZELX's monoclonal structure [3]. 3. The supposed increased tissue penetration of SLK does not correlate with improved clinical efficacy [3]. 4. The company lacked a reasonable basis for its positive claims regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [5]. Legal Representation - Robbins LLP is leading the class action and operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [6].